Allarity Therapeutics, Inc. (ALLR)

In March 2026, Allarity Therapeutics reported its full-year 2025 financial results, including reduced net loss and first revenue, leading to a stock price increase. Also in March 2026, the company closed a $20 million non-convertible debt financing from Streeterville Capital, resulting in a stock surge. In February 2026, Allarity Therapeutics announced the dosing of the first patients in a VA-funded Phase 2 trial for small cell lung cancer. In December 2025, the CEO highlighted progress towards Stenoparib FDA approval and outlined a strategic focus for 2026. In August 2025, Stenoparib received Fast Track designation from the FDA for advanced ovarian cancer. Also in August 2025, the company provided a second-quarter 2025 update, highlighting clinical progress, intellectual property expansion, and new partnerships.

As a clinical-stage biopharmaceutical company, Allarity Therapeutics, Inc. is primarily focused on research and development rather than commercial product sales. Therefore, there is no significant demand seasonality for its products and services.

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision medicine for cancer treatment. It develops personalized cancer therapies, with its primary product candidate being Stenoparib, a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. The company uses its Drug Response Predictor (DRP®) companion diagnostic technology to identify patients likely to benefit from specific therapies. Its business model centers on the clinical development of Stenoparib and the application of DRP® companion diagnostics.

Allarity Therapeutics, Inc. is headquartered in Boston, Massachusetts, and maintains a research and development facility in Hoersholm, Denmark. The company's operations are primarily conducted in Denmark and the United States.

Allarity Therapeutics has taken steps to address past regulatory and legal challenges, which can positively impact its brand reputation. The company finalized a settlement with the SEC and a class-action lawsuit against the company was dismissed. These resolutions help clear the path for the company to focus on clinical and corporate progress.

Allarity Therapeutics, Inc. has a mixed ownership structure including institutional investors, individual insiders, and retail investors. Institutional shareholders own approximately 8.17% of the company's stock, individual insiders own about 13.30%, and retail investors hold the largest portion at 78.53%. Major institutional owners include Renaissance Technologies Llc, Vanguard Group Inc, and Geode Capital Management, Llc. Key individual insider owners include Leon Sass and Thomas Jensen.